Reperfusion injury salvage kinase signalling: Taking a RISK for cardioprotection

Heart Failure Reviews

Volumn 12, Issue 3-4, 2007, Pages 217-234

  Hausenloy, Derek J ^a   Yellon, Derek M ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Erk1 2; Myocardial infarction; Protein kinases Akt; Reperfusion injury

Indexed keywords

ADENOSINE; ADRENOMEDULLIN; ATRIAL NATRIURETIC FACTOR ALPHA; CORTICOTROPIN; ESTROGEN; EXENDIN 4; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NATRIURETIC FACTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PROTEIN KINASE B; PROTEIN KINASE C INHIBITOR; RECOMBINANT ERYTHROPOIETIN; SITAGLIPTIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; UROCORTIN; VILDAGLIPTIN; CARRIER PROTEIN; PROTEIN KINASE;

ACUTE HEART INFARCTION; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART PROTECTION; HUMAN; MITOCHONDRIAL PERMEABILITY; NONHUMAN; OUTCOME ASSESSMENT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 34548008730     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-007-9026-1     Document Type: Article

References (184)

1. Yellon DM, Baxter GF (1999) Reperfusion injury revisited: Is there a role for growth factor signaling in limiting lethal reperfusion injury? Trends Cardiovasc Med 9:245-249
2. Hausenloy DJ, Yellon DM (2004) New directions for protecting the heart against ischaemia-reperfusion injury: Targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 61:448-460
3. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM (2004) Postconditioning: A form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 95:230-232
4. Hausenloy DJ, Tsang A, Mocanu M, Yellon DM (2005) Ischemic Preconditioning Protects by Activating Pro-Survival Kinases at Reperfusion. Am J Physiol Heart Circ Physiol 288:H971-H976
5. Murry CE, Jennings RB, Reimer KA (1986) Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 74:1124-1136
6. Yellon DM, Alkhulaifi AM, Pugsley WB (1993) Preconditioning the human myocardium. Lancet 342:276-277
7. Heusch G (2001) Nitroglycerin and delayed preconditioning in humans: Yet another new mechanism for an old drug? Circulation 103:2876-2878
8. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM (2005) Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol 288:H971-H976
9. Solenkova NV, Solodushko V, Cohen MV, Downey JM (2006) Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt. Am J Physiol Heart Circ Physiol 290:H441-H449
10. Lecour S, Suleman N, Deuchar GA et al (2005) Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation 112:3911-3918
11. Zhao ZQ, Corvera JS, Halkos ME et al (2003) Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285:H579-H588
12. Vinten-Johansen J, Yellon DM, Opie LH (2005) Postconditioning: A simple, clinically applicable procedure to improve revascularization in acute myocardial infarction. Circulation 112:2085-2088
13. Yellon DM, Opie LH (2006) Postconditioning for protection of the infarcting heart. Lancet 367:456-458
14. Laskey WK (2005) Brief repetitive balloon occlusions enhance reperfusion during percutaneous coronary intervention for acute myocardial infarction: A pilot study. Catheter Cardiovasc Interv 65:361-367
15. Staat P, Rioufol G, Piot C et al (2005) Postconditioning the human heart. Circulation 112:2143-2148
16. Ma X, Zhang X, Li C, Luo M (2006) Effect of postconditioning on coronary blood flow velocity and endothelial function and LV recovery after myocardial infarction. J Interv Cardiol 19:367-375
17. Yang X-C, Liu Y, Wang L-F, Cui L, Ge Y-G, Wang H-S, Li W-M, Xu Li, Ni Z-H, Liu H-S, Zhang L, Wang T, Jia H-M, Vinten-Johansen J., Zhao Z-Q (2006) Permanent reduction in myocardial infarct size by postconditioning in patients after primary coronary angioplasty. Circulation 114:II-812
18. Ravingerova T, Barancik M, Strniskova M (2003) Mitogen-activated protein kinases: A new therapeutic target in cardiac pathology. Mol Cell Biochem 247:127-138
19. Armstrong SC (2004) Protein kinase activation and myocardial ischemia/ reperfusion injury. Cardiovasc Res 61:427-436
20. Hausenloy DJ, Yellon DM (2006) Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 70:240-253
21. Inagaki K, Churchill E, Mochly-Rosen D (2006) Epsilon protein kinase C as a potential therapeutic target for the ischemic heart. Cardiovasc Res 70:222-230
22. Michel MC, Li Y, Heusch G (2001) Mitogen-activated protein kinases in the heart. Naunyn Schmiedebergs Arch Pharmacol 363:245-266
23. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL (1994) Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 94:1621-1628
24. Freude B, Masters TN, Robicsek F et al (2000) Apoptosis is initiated by myocardial ischemia and executed during reperfusion. J Mol Cell Cardiol 32:197-208
25. Zhao ZQ, Morris CD, Budde JM et al (2003) Inhibition of myocardial apoptosis reduces infarct size and improves regional contractile dysfunction during reperfusion. Cardiovasc Res 59:132-142
26. Mockridge JW, Marber MS, Heads RJ (2000) Activation of Akt during simulated ischemia/reperfusion in cardiac myocytes. Biochem Biophys Res Commun 270:947-952
27. Yamashita K, Kajstura J, Discher DJ et al (2001) Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts overexpressing insulin-like growth factor-1. Circ Res 88:609-614
28. Omura T, Yoshiyama M, Shimada T et al (1999) Activation of mitogen-activated protein kinases in in vivo ischemia/reperfused myocardium in rats. J Mol Cell Cardiol 31:1269-1279
29. Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ et al (1996) Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ Res 79:162-173
30. Matsui T, Li L, Wu JC et al (2002) Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 277:22896-22901
31. Miao W, Luo Z, Kitsis RN, Walsh K (2000) Intracoronary, adenovirus-mediated Akt gene transfer in heart limits infarct size following ischemia-reperfusion injury in vivo. J Mol Cell Cardiol 32:2397-2402
32. Yue TL, Wang C, Gu JL et al (2000) Inhibition of extracellular signal-regulated kinase enhances Ischemia/Reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res 86:692-699
33. Baxter GF, Mocanu MM, Brar BK, Latchman DS, Yellon DM (2001) Cardioprotective effects of transforming growth factor-beta1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPK. J Cardiovasc Pharmacol 38:930-939
34. Jonassen AK, Brar BK, Mjos OD, Sack MN, Latchman DS, Yellon DM (2000) Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. J Mol Cell Cardiol 32:757-764
35. Jonassen AK, Sack MN, Mjos OD, Yellon DM (2001) Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 89:1191-1198
36. Gao F, Gao E, Yue TL et al (2002) Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: The roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 105:1497-1502
37. Otani H, Yamamura T, Nakao Y et al (2000) Insulin-like growth factor-I improves recovery of cardiac performance during reperfusion in isolated rat heart by a wortmannin-sensitive mechanism. J Cardiovasc Pharmacol 35:275-281
38. Brar BK, Stephanou A, Pennica D, Latchman DS (2001) CT-1 mediated cardioprotection against ischaemic re-oxygenation injury is mediated by PI3 kinase, Akt and MEK1/2 pathways. Cytokine 16:93-96
39. Brar BK, Stephanou A, Liao Z et al (2001) Cardiotrophin-1 can protect cardiac myocytes from injury when added both prior to simulated ischaemia and at reoxygenation. Cardiovasc Res 51:265-274
40. Liao Z, Brar BK, Cai Q et al (2002) Cardiotrophin-1 (CT-1) can protect the adult heart from injury when added both prior to ischaemia and at reperfusion. Cardiovasc Res 53:902-910
41. Jiang ZS, Padua RR, Ju H et al (2002) Acute protection of ischemic heart by FGF-2: Involvement of FGF-2 receptors and protein kinase C. Am J Physiol Heart Circ Physiol 282:H1071-H1080
42. Hanlon PR, Fu P, Wright GL, Steenbergen C, Arcasoy MO, Murphy E (2005) Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: Role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J 19:1323-1325
43. Bullard AJ, Govewalla P, Yellon DM (2005) Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 100:397-493
44. Ueda K, Takano H, Hasegawa H et al (2006) Granulocyte colony stimulating factor directly inhibits myocardial ischemia-reperfusion injury through Akt-endothelial NO synthase pathway. Arterioscler Thromb Vasc Biol 26:e108-e113
45. Smith CC, Mocanu MM, Davidson SM, Wynne AM, Simpkin JC, Yellon DM (2006) Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects. Br J Pharmacol 149:5-13
46. Brar BK, Stephanou A, Knight R, Latchman DS (2002) Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. J Mol Cell Cardiol 34:483-492
47. Chanalaris A, Lawrence KM, Stephanou A et al (2003) Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes. J Mol Cell Cardiol 35:1295-1305
48. Brar BK, Jonassen AK, Stephanou A et al (2000) Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. J Biol Chem 275:8508-8514
49. Schulman D, Latchman DS, Yellon DM (2002) Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway. Am J Physiol Heart Circ Physiol 283:H1481-H1488
50. Valentim L, Laurence KM, Townsend PA et al (2006) Urocortin inhibits Beclin1-mediated autophagic cell death in cardiac myocytes exposed to ischaemia/reperfusion injury. J Mol Cell Cardiol 40:846-852
51. Yang XM, Krieg T, Cui L, Downey JM, Cohen MV (2004) NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through PI3K, ERK, and NO. J Mol Cell Cardiol 36:411-421
52. Kis A, Baxter GF, Yellon DM (2003) Limitation of myocardial reperfusion injury by AMP579, an adenosine A1/A2A receptor agonist: Role of A2A receptor and Erk1/2. Cardiovasc Drugs Ther 17:415-425
53. Park SS, Zhao H, Jang Y, Mueller RA, Xu Z (2006) N6-(3-iodobenzyl)-adenosine-5′-N-methylcarboxamide confers cardioprotection at reperfusion by inhibiting mitochondrial permeability transition pore opening via glycogen synthase kinase 3 beta. J Pharmacol Exp Ther 318:124-131
54. Bell RM, Yellon DM (2003) Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: The role of PI3K, Akt and eNOS. J Mol Cell Cardiol 35:185-193
55. Gross ER, Hsu AK, Gross GJ (2004) Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ Res 94:960-966
56. Hamid SA, Baxter GF (2005) Adrenomedullin limits reperfusion injury in experimental myocardial infarction. Basic Res Cardiol 100:387-396
57. Bose AK, Mocanu MM, Carr RD, Yellon DM (2005) Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 19:9-11
58. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM (2005) Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion Injury. Diabetes 54:146-151
59. Yang XM, Philipp S, Downey JM, Cohen MV (2006) Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol 101:311-318
60. Tissier R, Waintraub X, Couvreur N et al (2007) Pharmacological postconditioning with the phytoestrogen genistein. J Mol Cell Cardiol 42:79-87
61. Zhang SJ, Yang XM, Liu GS, Cohen MV, Pemberton K, Downey JM (2003) CGX-1051, a peptide from Conus snail venom, attenuates infarction in rabbit hearts when administered at reperfusion. J Cardiovasc Pharmacol 42:764-771
62. Chiari PC, Bienengraeber MW, Pagel PS, Krolikowski JG, Kersten JR, Warltier DC (2005) Isoflurane protects against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3-kinase signal transduction: Evidence for anesthetic-induced postconditioning in rabbits. Anesthesiology 102:102-109
63. Feng J, Lucchinetti E, Ahuja P, Pasch T, Perriard JC, Zaugg M (2005) Isoflurane postconditioning prevents opening of the mitochondrial permeability transition pore through inhibition of glycogen synthase kinase 3beta. Anesthesiology 103:987-995
64. Pagel PS, Krolikowski JG, Neff DA et al (2006) Inhibition of glycogen synthase kinase enhances isoflurane-induced protection against myocardial infarction during early reperfusion in vivo. Anesth Analg 102:1348-1354
65. Feng J, Fischer G, Lucchinetti E et al (2006) Infarct-remodeled myocardium is receptive to protection by isoflurane postconditioning: role of protein kinase B/Akt signaling. Anesthesiology 104:1004-1014
66. Weihrauch D, Krolikowski JG, Bienengraeber M, Kersten JR, Warltier DC, Pagel PS (2005) Morphine enhances isoflurane-induced postconditioning against myocardial infarction: The role of phosphatidylinositol-3-kinase and opioid receptors in rabbits. Anesth Analg 101:942-9, table
67. Krolikowski JG, Weihrauch D, Bienengraeber M, Kersten JR, Warltier DC, Pagel PS (2006) Role of Erk1/2, p70s6K, and eNOS in isoflurane-induced cardioprotection during early reperfusion in vivo. Can J Anaesth 53:174-182
68. Wang C, Neff DA, Krolikowski JG et al (2006) The influence of B-cell lymphoma 2 protein, an antiapoptotic regulator of mitochondrial permeability transition, on isoflurane-induced and ischemic postconditioning in rabbits. Anesth Analg 102:1355-1360
69. Bell RM, Yellon DM (2003) Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 41:508-515
70. Efthymiou CA, Mocanu MM, Yellon DM (2005) Atorvastatin and myocardial reperfusion injury: New pleiotropic effect implicating multiple prosurvival signaling. J Cardiovasc Pharmacol 45:247-252
71. Bopassa JC, Ferrera R, Gateau-Roesch O, Couture-Lepetit E, Ovize M (2006) PI 3-kinase regulates the mitochondrial transition pore in controlled reperfusion and postconditioning. Cardiovasc Res 69:178-185
72. Manintveld OC, Te Lintel HM, van den Bos EJ et al (2006) Cardiac effects of postconditioning depend critically on the duration of index ischemia. Am J Physiol Heart Circ Physiol 292:H1551-H1560
73. Yang XM, Philipp S, Downey JM, Cohen MV (2005) Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res Cardiol 100:57-63
74. Zhu M, Feng J, Lucchinetti E et al (2006) Ischemic postconditioning protects remodeled myocardium via the PI3K-PKB/Akt reperfusion injury salvage kinase pathway. Cardiovasc Res 72:152-162
75. Peng LY, Ma H, He JG et al (2006) [Ischemic postconditioning attenuates ischemia/reperfusion injury in isolated hypertrophied rat heart]. Zhonghua Xin Xue Guan Bing Za Zhi 34:685-689
76. Zhao, Z-Q, Wang, N-P, Mykytenko, J., Reeves, J, Deneve, J, Jiang, R, Zatta, AJ, Guyton, RA, Vinten-Johansen, J (2006) Postconditioning attenuates cardiac muscle cell apoptosis via translocation of survival kinases and opening of KATP channels in mitochondria. Circulation 114:II-261
77. Fujita M, Asanuma H, Hirata A et al (2007) Prolonged transient acidosis during early reperfusion contributes to the cardioprotective effects of postconditioning. Am J Physiol Heart Circ Physiol 292:H2004-H2008
78. Darling CE, Jiang R, Maynard M, Whittaker P, Vinten-Johansen J, Przyklenk K (2005) 'Postconditioning' via Stuttering reperfusion limits myocardial infarct size in rabbit hearts: Role of ERK 1/2. Am J Physiol Heart Circ Physiol 289:H1618-H1626
79. Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV (2004) Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 44:1103-1110
80. Sun HY, Wang NP, Halkos M et al (2006) Postconditioning attenuates cardiomyocyte apoptosis via inhibition of JNK and p38 mitogen-activated protein kinase signaling pathways. Apoptosis 11:1583-1593
81. Philipp S, Yang XM, Cui L, Davis AM, Downey JM, Cohen MV (2006) Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade. Cardiovasc Res 70:308-314
82. + channel and protein kinase C activation. Basic Res Cardiol 101:180-189
83. Fantinelli JC, Mosca SM (2007) Comparative effects of ischemic pre and postconditioning on ischemia-reperfusion injury in spontaneously hypertensive rats (SHR). Mol Cell Biochem 296:45-51
84. Zatta AJ, Kin H, Lee G et al (2006) Infarct-sparing effect of myocardial postconditioning is dependent on protein kinase C signalling. Cardiovasc Res 70:315-324
85. Suleman N, Opie L, Lecour S (2006) Ischemic postconditioning confers cardioprotection via phosporylation of STAT-3. J Mol Cell Cardiol 40:155
86. Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M (2005) Postconditioning inhibits mitochondrial permeability transition. Circulation 111:194-197
87. Burley DS, Baxter GF (2005) Post-conditioning is dependent on pkg activation in early reperfusion. J Mol Cell Cardiol 38:28
88. da Silva R, Grampp T, Pasch T, Schaub MC, Zaugg M (2004) Differential activation of mitogen-activated protein kinases in ischemic and anesthetic preconditioning. Anesthesiology 100:59-69
89. Fryer RM, Pratt PF, Hsu AK, Gross GJ (2001) Differential activation of extracellular signal regulated kinase isoforms in preconditioning and opioid-induced cardioprotection. J Pharmacol Exp Ther 296:642-649
90. Fryer RM, Patel HH, Hsu AK, Gross GJ (2001) Stress-activated protein kinase phosphorylation during cardioprotection in the ischemic myocardium. Am J Physiol Heart Circ Physiol 281:H1184-H1192
91. Sanada S, Asanuma H, Minamino T et al (2004) Optimal windows of statin use for immediate infarct limitation: 5′-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase. Circulation 110:2143-2149
92. Wynne AM, Mocanu MM, Yellon DM (2005) Pioglitazone mimics preconditioning in the isolated perfused rat heart: A role for the prosurvival kinases PI3K and P42/44MAPK. J Cardiovasc Pharmacol 46:817-822
93. Bell RM, Clark JE, Hearse DJ, Shattock MJ (2007) Reperfusion kinase phosphorylation is essential but not sufficient in the mediation of pharmacological preconditioning: Characterisation in the bi-phasic profile of early and late protection. Cardiovasc Res 73:153-163
94. Ping P, Murphy E (2000) Role of p38 mitogen-activated protein kinases in preconditioning: A detrimental factor or a protective kinase? Circ Res 86:921-922
95. Hausenloy DJ, Yellon DM (2007) Preconditioning and postconditioning: United at reperfusion. Pharmacol Therapeutics (in press)
96. Kin H, Zhao ZQ, Sun HY et al (2004) Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 62:74-85
97. Griffiths EJ, Halestrap AP (1995) Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 307(Pt 1):93-98
98. Di Lisa F, Menabo R, Canton M, Barile M, Bernardi P (2001) Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem 276:2571-2575
99. Kim JS, Jin Y, Lemasters JJ (2006) Reactive oxygen species, but not Ca2+ overloading, trigger pH- and mitochondrial permeability transition-dependent death of adult rat myocytes after ischemia-reperfusion. Am J Physiol Heart Circ Physiol 290:H2024-H2034
100. Crompton M (1999) The mitochondrial permeability transition pore and its role in cell death. Biochem J 341(Pt 2):233-249
101. Hausenloy DJ, Yellon DM (2003) The mitochondrial permeability transition pore: Its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 35:339-341
102. Hausenloy DJ, Duchen MR, Yellon DM (2003) Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res 60:617-625
103. Lefer AM, Tsao P, Aoki N, Palladino MA Jr (1990) Mediation of cardioprotection by transforming growth factor-beta. Science 249:61-64
104. Kulik G, Klippel A, Weber MJ (1997) Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 17:1595-1606
105. Parrizas M, Saltiel AR, LeRoith D (1997) Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J Biol Chem 272:154-161
106. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K (2000) Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 101:660-667
107. Hong F, Kwon SJ, Jhun BS et al (2001) Insulin-like growth factor-1 protects H9c2 cardiac myoblasts from oxidative stress-induced apoptosis via phosphatidylinositol 3-kinase and extracellular signal-regulated kinase pathways. Life Sci 68:1095-1105
108. Chao W, Matsui T, Novikov MS et al (2003) Strategic advantages of insulin-like growth factor-I expression for cardioprotection. J Gene Med 5:277-286
109. Wang L, Ma W, Markovich R, Chen JW, Wang PH (1998) Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res 83:516-522
110. Yamamura T, Otani H, Nakao Y, Hattori R, Osako M, Imamura H (2001) IGF-I differentially regulates Bcl-xL and Bax and confers myocardial protection in the rat heart. Am J Physiol Heart Circ Physiol 280:H1191-H1200
111. Pennica D, King KL, Shaw KJ et al (1995) Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci USA 92:1142-1146
112. Sheng Z, Pennica D, Wood WI, Chien KR (1996) Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival. Development 122:419-428
113. Sheng Z, Knowlton K, Chen J, Hoshijima M, Brown JH, Chien KR (1997) Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy J Biol Chem 272:5783-5791
114. Buehler A, Martire A, Strohm C et al (2002) Angiogenesis-independent cardioprotection in FGF-1 transgenic mice. Cardiovasc Res 55:768-777
115. Heusch G (2006) Obesity-a risk factor or a RISK factor for myocardial infarction? Br J Pharmacol 149:1-3
116. Harada M, Qin Y, Takano H et al (2005) G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 11:305-311
117. Kitamura K, Kangawa K, Kawamoto M et al (1993) Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192:553-560
118. Kato K, Yin H, Agata J, Yoshida H, Chao L, Chao J (2003) Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion. Am J Physiol Heart Circ Physiol 285:H1506-H1514
119. Yin H, Chao L, Chao J (2004) Adrenomedullin protects against myocardial apoptosis after ischemia/reperfusion through activation of Akt-GSK signaling. Hypertension 43:109-116
120. Okumura H, Nagaya N, Itoh T et al (2004) Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway. Circulation 109:242-248
121. Deacon CF (2004) Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53:2181-2189
122. D'Souza SP, Yellon DM, Martin C et al (2003) B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol 284:H1592-H1600
123. Sangawa K, Nakanishi K, Ishino K, Inoue M, Kawada M, Sano S (2004) Atrial natriuretic peptide protects against ischemia-reperfusion injury in the isolated rat heart. Ann Thorac Surg 77:233-237
124. Patten RD, Pourati I, Aronovitz MJ et al (2004) 17beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res 95:692-699
125. Lee TM, Lin MS, Chou TF, Tsai CH, Chang NC (2004) Adjunctive 17beta-estradiol administration reduces infarct size by altered expression of canine myocardial connexin43 protein. Cardiovasc Res 63:109-117
126. Stefano GB, Prevot V, Beauvillain JC et al (2000) Cell-surface estrogen receptors mediate calcium-dependent nitric oxide release in human endothelia. Circulation 101:1594-1597
127. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK (2000) Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407:538-541
128. Piriou V, Chiari P, Gateau-Roesch O et al (2004) Desflurane-induced preconditioning alters calcium-induced mitochondrial permeability transition. Anesthesiology 100:581-588
129. Raphael J, Abedat S, Rivo J et al (2006) Volatile anesthetic preconditioning attenuates myocardial apoptosis in rabbits after regional ischemia and reperfusion via Akt signaling and modulation of Bcl-2 family proteins. J Pharmacol Exp Ther 318:186-194
130. Schlack W, Preckel B, Stunneck D, Thamer V (1998) Effects of halothane, enflurane, isoflurane, sevoflurane and desflurane on myocardial reperfusion injury in the isolated rat heart. Br J Anaesth 81:913-919
131. Preckel B, Schlack W, Comfere T, Obal D, Barthel H, Thamer V (1998) Effects of enflurane, isoflurane, sevoflurane and desflurane on reperfusion injury after regional myocardial ischaemia in the rabbit heart in vivo. Br J Anaesth 81:905-912
132. Tessier-Vetzel D, Tissier R, Waintraub X, Ghaleh B, Berdeaux A (2006) Isoflurane inhaled at the onset of reperfusion potentiates the cardioprotective effect of ischemic postconditioning through a NO-dependent mechanism. J Cardiovasc Pharmacol 47:487-492
133. Venkatapuram S, Wang C, Krolikowski JG et al (2006) Inhibition of apoptotic protein p53 lowers the threshold of isoflurane-induced cardioprotection during early reperfusion in rabbits. Anesth Analg 103:1400-1405
134. Di Napoli P, Antonio TA, Grilli A et al (2001) Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: An ex vivo study in isolated working rat hearts. Cardiovasc Res 51:283-293
135. Kureishi Y, Luo Z, Shiojima I et al (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6:1004-1010
136. Schwartz LM, Lagranha CJ (2006) Ischemic postconditioning during reperfusion activates Akt and ERK without protecting against lethal myocardial ischemia-reperfusion injury in pigs. Am J Physiol Heart Circ Physiol 290:H1011-H1018
137. Heusch G (2004) Postconditioning: Old wine in a new bottle? J Am Coll Cardiol 44:1111-1112
138. Kin H, Zatta AJ, Lofye MT et al (2005) Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res 67:124-133
139. Kin H, Zatta AJ, Jiang R, Reeves JG, Mykytenko J, Sorescu GP, Zhao Z-Q, Wang NP, Guyton RA, Vinten-Johansen J (2005) Activation of opioid receptors mediates the infarct size reduction by Postconditioning. J Mol Cell Cardiol 38:827
140. Marber MS, Latchman DS, Walker JM, Yellon DM (1993) Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 88:1264-1272
141. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ (2001) p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 98:9666-9670
142. Juhaszova M, Zorov DB, Kim SH et al (2004) Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113:1535-1549
143. Davidson SM, Hausenloy D, Duchen MR, Yellon DM (2006) Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol 38:414-419
144. Costa AD, Garlid KD, West IC et al (2005) Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ Res 97:329-336
145. Andrukhiv A, Costa AD, West IC, Garlid KD (2006) Opening mitoKATP increases superoxide generation from complex I of the electron transport chain. Am J Physiol Heart Circ Physiol 291:H2067-H2074
146. 2 inhibit the mitochondrial permeability transition. J Biol Chem 281:20801-20808
147. Jaburek M, Costa AD, Burton JR, Costa CL, Garlid KD (2006) Mitochondrial PKC{epsilon} and Mitochondrial ATP-Sensitive K + Channel Copurify and Coreconstitute to Form a Functioning Signaling Module in Proteoliposomes. Circ Res 99:878-883
148. Kim JS, Ohshima S, Pediaditakis P, Lemasters JJ (2004) Nitric oxide: A signaling molecule against mitochondrial permeability transition- and pH-dependent cell death after reperfusion. Free Radic Biol Med 37:1943-1950
149. Yamaguchi H, Wang HG (2001) The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 20:7779-7786
150. Zuurbier CJ, Eerbeek O, Meijer AJ (2005) Ischemic preconditioning, insulin, and morphine all cause hexokinase redistribution. Am J Physiol Heart Circ Physiol 289:H496-H499
151. Pastorino JG, Hoek JB, Shulga N (2005) Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res 65:10545-10554
152. 2+ storage. Cardiovasc Res 70:346-353
153. Dosenko VE, Nagibin VS, Tumanovskaya LV, Zagoriy VY, Moibenko AA, Vaage J (2006) Proteasomal proteolysis in anoxia-reoxygenation, preconditioning and postconditioning of isolated cardiomyocytes. Pathophysiology 13:119-125
154. Hahn HS, Yussman MG, Toyokawa T et al (2002) Ischemic protection and myofibrillar cardiomyopathy: Dose-dependent effects of in vivo deltaPKC inhibition. Circ Res 91:741-748
155. Inagaki K, Hahn HS, Dorn GW, Mochly-Rosen D (2003) Additive protection of the ischemic heart ex vivo by combined treatment with delta-protein kinase C inhibitor and epsilon-protein kinase C activator. Circulation 108:869-875
156. Noma K, Oyama N, Liao JK (2006) Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 290:C661-C668
157. Loirand G, Guerin P, Pacaud P (2006) Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 98:322-334
158. Bao W, Hu E, Tao L et al (2004) Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. Cardiovasc Res 61:548-558
159. Wolfrum S, Dendorfer A, Rikitake Y et al (2004) Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 24:1842-1847
160. Hamid S, Bower HS, Baxter GF (2007) Rho-kinase plays a major role as a mediator of irreversible injury in reperfused myocardium. Am J Physiol Heart Circ Physiol Jan 12; [Epub ahead of print]
161. Asakura M, Jiyoong K, Minamino T, Shintani Y, Asanuma H, Kitakaze M (2004) Rationale and design of a large-scale trial using atrial natriuretic peptide (ANP) as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction: Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage by ANP (J-WIND-ANP). Circ J 68:95-100
162. Schwartz GG, Olsson AG, Ezekowitz MD et al (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: TAe MIRACL study: a randomized controlled trial. JAMA 285:1711-1718
163. Cannon CP, Braunwald E, McCabe CH et al (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495-1504
164. Mahaffey KW, Puma JA, Barbagelata NA et al (1999) Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial: The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 34:1711-1720
165. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW (2005) A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 45:1775-1780
166. Nikolaidis LA, Mankad S, Sokos GG et al (2004) Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109:962-965
167. Ehrenreich H, Hasselblatt M, Dembowski C et al (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8:495-505
168. Lipsic E, van der MP, Voors AA et al (2006) A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: A randomized feasibility and safety study. Cardiovasc Drugs Ther 20:135-141
169. Lee TM, Su SF, Chou TF, Tsai CH (2002) Pharmacologic preconditioning of estrogen by activation of the myocardial adenosine triphosphate-sensitive potassium channel in patients undergoing coronary angioplasty. J Am Coll Cardiol 39:871-877
170. Shimokawa H, Hiramori K, Iinuma H et al (2002) Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol 40:751-761
171. Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E (2005) Effects of fasudil in acute ischemic stroke: Results of a prospective placebo-controlled double-blind trial. J Neurol Sci 238:31-39
172. Kishi T, Hirooka Y, Masumoto A et al (2005) Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation 111:2741-2747
173. Chyrchel M, Rakowski T, Rzeszutko L et al (2006) Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome. Kardiol Pol 64:1357-1362
174. Marzilli M, Orsini E, Marraccini P, Testa R (2000) Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 101:2154-2159
175. Quintana M, Hjemdahl P, Sollevi A et al (2003) Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study. Eur J Clin Pharmacol 59:1-9
176. Mehta SR, Yusuf S, Diaz R et al (2005) Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: The CREATE-ECLA randomized controlled trial. JAMA 293:437-446
177. Jonassen AK, Aasum E, Riemersma RA, Mjos OD, Larsen TS (2000) Glucose-insulin-potassium reduces infarct size when administered during reperfusion. Cardiovasc Drugs Ther 14:615-623
178. Apstein CS, Opie LH (2005) A challenge to the metabolic approach to myocardial ischaemia. Eur Heart J 26:956-959
179. Belhomme D, Peynet J, Louzy M, Launay JM, Kitakaze M, Menasche P (1999) Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation 100:II340-II344
180. Van Der Linden PJ, Daper A, Trenchant A, De Hert SG (2003) Cardioprotective effects of volatile anesthetics in cardiac surgery. Anesthesiology 99:516-517
181. Symons JA, Myles PS (2006) Myocardial protection with volatile anaesthetic agents during coronary artery bypass surgery: A meta-analysis. Br J Anaesth 97:127-136
182. Takano H, Hasegawa H, Kuwabara Y et al (2006) Feasibility and safety of granulocyte colony-stimulating factor treatment in patients with acute myocardial infarction. Int J Cardiol
183. Kang HJ, Kim HS, Zhang SY et al (2004) Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: The MAGIC cell randomised clinical trial. Lancet 363:751-756
184. Hill JM, Syed MA, Arai AE et al (2005) Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol 46:1643-1648